PubRank

Hiroya Taniguchi

Author PubWeight™ 15.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005 6.23
2 Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun 2008 0.97
3 Leptomeningeal carcinomatosis associated with gastric cancer. Int J Clin Oncol 2011 0.91
4 Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer. Int J Clin Oncol 2011 0.84
5 Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn J Clin Oncol 2012 0.84
6 Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer Chemother Pharmacol 2015 0.83
7 Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment. Int J Clin Oncol 2013 0.83
8 Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells. Int J Oncol 2010 0.82
9 CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Cancer Chemother Pharmacol 2013 0.79
10 Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis. Int J Clin Oncol 2010 0.79
11 Pseudomyxoma peritonei occurring after an uneventful 23 years interval from appendectomy. Intern Med 2007 0.76
12 Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy. Int J Clin Oncol 2012 0.76
13 Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature. Medicine (Baltimore) 2017 0.75
14 S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy. Jpn J Clin Oncol 2011 0.75
15 Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
. Int J Clin Pharmacol Ther 2017 0.75
16 [Lower G. I./colon and rectum cancer. III. Current topics concerning postoperative adjuvant chemotherapy]. Gan To Kagaku Ryoho 2010 0.75
17 Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody. Oncology 2017 0.75
18 Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer. Oncology 2017 0.75
19 Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals. Int J Clin Oncol 2014 0.75